Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany.
Department of Electronic Components and Circuits, University Duisburg-Essen, Duisburg, Germany.
Biomed Eng Online. 2021 Oct 12;20(1):102. doi: 10.1186/s12938-021-00938-9.
Retinal degenerative diseases, e.g., retinitis pigmentosa, cause a severe decline of the visual function up to blindness. Treatment still remains difficult; however, implantation of retinal prostheses can help restoring vision. In this study, the biocompatibility and surgical feasibility of a newly developed epiretinal stimulator (OPTO-EPIRET) was investigated. The previously developed implant was extended by an integrated circuit-based optical capturing, which will enable the immediate conversion of the visual field into stimulation patterns to stimulate retinal ganglion cells.
The biocompatibility of the OPTO-EPIRET was investigated in vitro using the two different cell lines L-929 and R28. Direct and indirect contact were analyzed in terms of cell proliferation, cell viability, and gene expression. The surgical feasibility was initially tested by implanting the OPTO-EPIRET in cadaveric rabbit eyes. Afterwards, inactive devices were implanted in six rabbits for feasibility and biocompatibility testings in vivo. In follow-up controls (1-12 weeks post-surgery), the eyes were examined using fundoscopy and optical coherence tomography. After finalization, histological examination was performed to analyze the retinal structure. Regarding the in vitro biocompatibility, no significant influence on cell viability was detected (L929: < 1.3% dead cells; R-28: < 0.8% dead cells). The surgery, which comprised phacoemulsification, vitrectomy, and implantation of the OPTO-EPIRET through a 9-10 mm corneal incision, was successfully established. The implant was fixated with a retinal tack. Vitreal hemorrhage or retinal tearing occurred as main adverse effects. Transitional corneal edema caused difficulties in post-surgical imaging.
The OPTO-EPIRET stimulator showed a good biocompatibility profile in vitro. Furthermore, the implantation surgery was shown to be feasible. However, further design optimization steps are necessary to avoid intra- and postoperative complications. Overall, the OPTO-EPIRET will allow for a wide visual field and good visual acuity due to a high density of electrodes in the central retina.
视网膜退行性疾病,如色素性视网膜炎,会导致严重的视力下降,甚至失明。目前治疗仍然很困难;然而,视网膜假体的植入可以帮助恢复视力。在这项研究中,我们研究了一种新开发的视网膜上刺激器(OPTO-EPIRET)的生物相容性和手术可行性。之前开发的植入物通过基于集成电路的光学捕获得到扩展,这将能够立即将视野转换为刺激模式,以刺激视网膜神经节细胞。
我们使用两种不同的细胞系 L-929 和 R28 在体外研究了 OPTO-EPIRET 的生物相容性。直接和间接接触分析了细胞增殖、细胞活力和基因表达。最初通过将 OPTO-EPIRET 植入尸体兔眼来测试手术可行性。然后,将无活性的设备植入六只兔子体内,进行体内可行性和生物相容性测试。在后续对照(术后 1-12 周)中,使用眼底镜和光学相干断层扫描检查眼睛。完成后,进行组织学检查以分析视网膜结构。关于体外生物相容性,未检测到对细胞活力有显著影响(L929:<1.3%死亡细胞;R-28:<0.8%死亡细胞)。手术包括超声乳化、玻璃体切除术和通过 9-10mm 角膜切口植入 OPTO-EPIRET。植入物用视网膜钉固定。主要的不良反应是玻璃体积血或视网膜撕裂。过渡性角膜水肿导致术后成像困难。
OPTO-EPIRET 刺激器在体外表现出良好的生物相容性。此外,植入手术是可行的。然而,需要进一步的设计优化步骤来避免术中及术后并发症。总的来说,由于中央视网膜的电极密度高,OPTO-EPIRET 将允许更宽的视野和更好的视力。